U.S.-based health insurers Cigna Corp and Aetna Inc. have struck deals with Novartis AG for a performance-based price for the Swiss drugmaker's new heart drug, Entresto, the companies said on Monday.
The agreements are among the few performance-based deals that have been made public by drugmakers and U.S. managed-care companies, which say they have been having more discussions about linking price to health outcomes in order to cut unneeded drug spending.
Read Full Article »